159 related articles for article (PubMed ID: 37756561)
1. DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H; Graves JD; Garan LAW; Lin FT; Lin WC
Cancer Res Commun; 2023 Oct; 3(10):2096-2112. PubMed ID: 37756561
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.
Liu K; Lin FT; Graves JD; Lee YJ; Lin WC
Proc Natl Acad Sci U S A; 2017 May; 114(19):E3766-E3775. PubMed ID: 28439015
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
4. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
5. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
Zhao Y; Zhou K; Xia X; Guo Y; Tao L
Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
[TBL] [Abstract][Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
8. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.
Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; Maretto M; Bassetti E; Caiazzo R; D'Orazi G; Cirone M
Exp Cell Res; 2021 Nov; 408(2):112879. PubMed ID: 34653407
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
[TBL] [Abstract][Full Text] [Related]
11. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
12. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
14. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
15. Kub5-Hera
Motea EA; Fattah FJ; Xiao L; Girard L; Rommel A; Morales JC; Patidar P; Zhou Y; Porter A; Xie Y; Minna JD; Boothman DA
Clin Cancer Res; 2018 Dec; 24(24):6459-6470. PubMed ID: 30108102
[TBL] [Abstract][Full Text] [Related]
16. RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
Liu P; Lin C; Liu L; Lu Z; Tu Z; Liu H
J Biol Chem; 2022 Sep; 298(9):102354. PubMed ID: 35952757
[TBL] [Abstract][Full Text] [Related]
17. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
18. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
20. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]